Pharmacists in West Harrison, NY Accepting Medicare

6 Pharmacists found. Showing 1 - 6

Heeyeon Kim Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 59 Harrison St, West Harrison, NY 10604 Phone: 914-414-9368

Kimberly Sager, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 500 Westchester Ave, West Harrison, NY 10604 Phone: 914-367-7015

Frank Zappa Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 500 Westchester Ave, West Harrison, NY 10604 Phone: 914-367-7015

Arwa Mohamed, PHARMD Pharmacist - Oncology Medicare: Not Enrolled in Medicare Practice Location: 500 Westchester Ave, West Harrison, NY 10604 Phone: 914-367-7015

Jennie John, RPH Pharmacist - Oncology Medicare: Not Enrolled in Medicare Practice Location: 500 Westchester Ave, West Harrison, NY 10604 Phone: 914-367-7015

Luke Nitis, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 500 Westchester Ave, West Harrison, NY 10604 Phone: 914-367-7208

News Archive

Four subtypes of blood cancer identified

Scientists at Dana-Farber Cancer Institute and collaborators have identified four distinct genetic subtypes of multiple myeloma, a deadly blood cancer, that have different prognoses and might be treated most effectively with drugs specifically targeted to those subtypes.

Three commonly used NSAIDs affect cell membranes, produce unwanted side effects

Researchers have discovered that three commonly used nonsteroidal anti-inflammatory drugs, or NSAIDs, alter the activity of enzymes within cell membranes. Their finding suggests that, if taken at higher-than-approved doses and/or for long periods of time, these prescription-level NSAIDs and other drugs that affect the membrane may produce wide-ranging and unwanted side effects.

Newly found peptide may reduce desire for food

Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.

Genkyotex announces positive results from GKT137831 Phase I studies on healthy subjects

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.

Read more Medical News

› Verified 5 days ago